Grace Therapeutics, Inc. (GRCE)
NASDAQ: GRCE · Real-Time Price · USD
2.430
-0.040 (-1.62%)
Jul 20, 2026, 4:00 PM EDT - Market closed
Grace Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
39.55M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veru Inc. | 16.89M |
| Apollomics | 8.84M |
| CervoMed | 2.09M |
| Nutriband | 1.80M |
| RenovoRx | 1.49M |
| Hyperion DeFi | 1.04M |
GRCE News
- 4 weeks ago - Grace Therapeutics reports FY26 EPS (47c) vs (79c) last year - TheFly
- 4 weeks ago - Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update - GlobeNewsWire
- 4 weeks ago - Grace Therapeutics Annual report: Q4 2026 - Filings
- 4 weeks ago - Grace Therapeutics Earnings release: Q4 2026 - Filings
- 4 weeks ago - Grace Therapeutics Slides: Corporate presentation - Filings
- 3 months ago - Grace Therapeutics price target lowered to $4 from $11 at Craig-Hallum - TheFly
- 3 months ago - Grace Therapeutics price target lowered to $8 from $12 at TD Cowen - TheFly
- 3 months ago - Grace Therapeutics down 48% after receipt of CRL from FDA for GTx-104 - TheFly